|
|
||||||||
CUTTING EDGE |
Department of Cardiovascular Pharmacology, SmithKline Beecham Pharmaceuticals, King of Prussia, PA 19406
| Abstract |
|---|
|
|
|---|
4.0-kb mRNA transcript and differs
from the known human CXCR4 by the first 9 aa in the functionally
important NH2-terminal extracellular domain of the
receptor. CXCR4-Lo-transfected rat basophil leukemia-2H3 cells
responded to SDF-1 with a transient rise of intracellular
Ca2+ concentration and by undergoing chemotaxis. Expression
of CXCR4-Lo is noteworthy, as it may have differential affinity as a
coreceptor for HIV strains in comparison with CXCR4. Furthermore,
CXCR4-Lo may also provide a functional backup to CXCR4 during
embryogenesis. | Introduction |
|---|
|
|
|---|
The intron splice junction of murine CXCR4 gene has an in-frame alternative GT splice donor site within exon 1, causing expression of an isoform that is shorter by 2 aa in the NH2-terminal domain (18, 19). Both murine CXCR4 isoforms are coexpressed in all tissues examined and use SDF-1 as their functional ligand. The human CXCR4 gene also contains 2 exons of 103- and 1563-bp size (20, 21), interrupted by a 2132-bp intron precisely between codons 5 (AGT/Ser) and 6 (ATA/Ile) of the NH2-terminal domain (20). Although an alternative splice donor site (GT) similar to the murine CXCR4 gene exists 9 bp downstream from the last codon of the first exon in human CXCR4 (20), there is no molecular evidence it causes expression of multiple transcripts (21, 22).
In contrast, our initial observation of two distinct mRNA transcripts in HUVECs (7) strongly revealed the possible existence and expression of a unique human CXCR4 splice variant. In this report, we demonstrate that the human CXCR4 gene indeed has a larger unspliced form of the receptor, CXCR4-Lo, that differs with CXCR4 in the NH2-terminal region by 9 aa. We also show that CXCR4-Lo is functional and differentially expressed in human tissues.
| Materials and Methods |
|---|
|
|
|---|
The CXCR4-Lo cDNA clone was identified from the SmithKline
Beecham cDNA database by searching for expressed sequence tags (ESTs)
with identity to human CXCR4 and analyzing their open reading frames
(ORFs) for NH2-terminal sequence variants using
the FASTA and BLAST algorithms of the GCG software package (Genetics
Computer Group, Madison, WI). Total RNA was isolated from HL-60 cells
by the Tri-reagent procedure (Molecular Research Center, Cincinnati,
OH), and CXCR4-Lo specific cDNA was amplified with two sets of
specific primers, Lo-346 and Lo-1071 (Lo-346, forward:
5'AGAGAGAGAACTAGTCTCGC, reverse: 5'AGAGGCAAAGGAATGGACAT; and Lo-1071,
forward: 5'ATGTCCATTCCTTTGCCTCT, reverse: 5'AGCTGGAGTGAAAACTTGAAG)
using the RNA-PCR kit from Perkin-Elmer (Foster City, CA), according to
the manufacturers protocol. The 346-bp PCR product amplified with
Lo-346 primers was used as a CXCR4-Lo-specific cDNA probe, while the
515-bp cDNA fragment of CXCR4 (7) was used as a common
probe for both isoforms. Human tissue Northern blots were purchased
from Clontech (Palo Alto, CA). The GAPDH probe (Clontech) was used to
normalize the amount of total RNA loaded in all lanes.
[
-32P]dCTP-labeled DNA probes were used for
high-stringency hybridizations as described earlier (7).
Northern blots were analyzed using phosphorimager densitometric scans
(Molecular Devices, Menlo Park, CA).
Transfection of rat basophil leukemia (RBL)-2H3 cells
Full-length CXCR4 and CXCR4-Lo cDNAs were subcloned into pCRR3.1 (Invitrogen, San Diego, CA) eukaryotic expression vectors, and their orientation was confirmed by sequencing. The resultant expression constructs were transfected into RBL cells (American Type Culture Collection, Manassas, VA) by electroporation, and transfected cells were selected by using RPMI 1640 media containing 800 µg/ml G-418 (Life Technologies, Rockville, MD). CXCR4 and CXCR4-Lo specific mRNA expression was confirmed by Northern blot analysis. FACS analysis to compare surface expression of CXCR4 and CXCR4-Lo in transfected RBL cell lines was done with the CXCR4-specific 12G5 mAb as described before for endothelial cells (7).
Functional characterization of CXCR4-Lo in stably transfected RBL cells
Mobilization of [Ca2+]i in transfected RBL cells
was measured by fluorometric imaging plate reader (FLIPR; Molecular
Devices) analysis (23). Briefly, 6 x
104 cells were added per well of a 96-well plate
and grown for 24 h. Cells were loaded with Fluo-3 AM
dissolved in dye-loading buffer (Eagles minimum essential medium
with 0.1% BSA and 15 mM sulpinpyrozone) for 60 min at 37°C.
Following this, the dye-loading buffer was removed, and 100 µl
hydrolysis buffer (15 mM sulfinpyrozone in Eagles minimum essential
medium) was added to each well and incubated for 10 min at 37°C.
Relative changes in fluorescence counts as a response to
[Ca2+]i flux after
addition of SDF-1
(R&D Systems, Minneapolis, MN) are expressed as
FLIPR units.
SDF-1-induced migration of transfected RBL cells was done as described for HUVECs (7). Briefly, 5 x 105 cells in serum-free RPMI 1640 medium (with 0.25% BSA) were added in the top chamber of a 6.5-mm diameter, 5-µm pore poly carbonate transwell culture insert (Costar, Cambridge, MA). Incubation was conducted at 37°C in a 5% CO2 incubator for 18 h. Migrated cells in the lower chamber were counted with a ZM Coulter counter (Coulter Diagnostics, Hialeah, FL). Percent migration was calculated based on the total initial input of cells per well.
| Results and Discussion |
|---|
|
|
|---|
We previously demonstrated the expression of two distinct
mRNAs,
1.7-kb and
4.0-kb transcripts for CXCR4 in
HUVECs, and had speculated on the putative existence of an
alternatively spliced isoform (7). Subsequently, we used
bioinformatics to identify homologous ESTs with sequence variation in
the NH2-terminal region of the EC domain of
CXCR4. Two variant cDNA clones, designated as CXCR4-Lo, were isolated
from a human neutrophil cDNA library and sequenced. Unlike CXCR4, the
1071-bp ORF of CXCR4-Lo cDNA clone is encoded by a single exon. The
coding region is initiated from an alternate in-frame ATG start codon
found within the intron sequence characterized in the recently
published genomic structure for CXCR4 (20, 21) and 25-bp
upstream of the known AG acceptor site used for intron splicing (Fig. 1
, A and B).
Significantly, the predicted full-length 357-aa CXCR4-Lo receptor (not
shown, GenBank accession no. AF147204) contains a longer
neo-NH2-terminal EC domain that is different from
the corresponding CXCR4 sequence by the first 9 aa residues
M-S-I-P-L-P-L-L-Q (Fig. 1
, A and B), while the
remaining sequence is identical. The 3' untranslated region of CXCR4-Lo
(not shown) has an AATAAA polyadenylation consensus signal and is
identical with the published genomic sequence of human CXCR4
(20).
|
To further test this hypothesis, and also address the question whether
the two human CXCR4 isoforms are products of a single gene, RT-PCR
primers (Lo-346 and Lo-1071) were designed to selectively amplify from
the unique 5'-end of CXCR4-Lo transcripts from HL-60 cells.
Hybridization of amplified cDNA with the CXCR4-Lo cDNA-specific 346-bp
DNA probe revealed the expected specificity of the 1071-bp PCR product
(Fig. 1
C). In addition, Northern analysis with the 346-bp
probe also confirmed expression of the
4.0-kb CXCR4-Lo mRNA in PBLs
and other tissues (Fig. 1
D).
The qualitative comparison of CXCR4 and CXCR4-Lo mRNA expression in
tissues was done using the common 515-bp cDNA probe (7).
As noted previously (4, 5), CXCR4 is highly expressed in
most human tissues upon Northern blot analysis (Fig. 2
). While overall CXCR4-Lo expression is
either proportionally lower or absent in all tissues (Fig. 2
A), there is relatively more expression of its mRNA in
spleen, lung, PBLs, and cancer cell lines like HL-60 and MOLT-4. Such
selective differences in tissue-specific expression of the unspliced
CXCR4-Lo isoform implies that its expression is regulated, rather than
being caused by a random or passive absence of normal splicing.
However, additional studies including the role of the "coding
intron" in modulating transcription are desirable to assess the
functional significance of CXCR4-Lo expression. Furthermore, although
CXCR4 expression is low in whole brain (Fig. 2
, A and
B), especially high mRNA expression was observed in spinal
cord, medulla, and frontal lobe, with moderate to low expression in
putamen, temporal lobe, cerebellum, and cerebellar cortex. Significant,
though lower, concomitant expression of the
4.0-kb CXCR4-Lo mRNA was
also observed in the spinal cord, medulla, substantia nigra, and
subthalamic nucleus (Fig. 2
B). The functional consequence of
such an expression pattern of both CXCR4 and CXCR4-Lo in brain is not
known, although it was recently shown that fetal cerebellar development
is impaired in the CXCR4-knockout mice (10).
|
Stably transfected RBL cell lines were generated from full-length
ORFs of both CXCR4 and CXCR4-Lo, and their functional response to
SDF-1
-mediated [Ca2+]i
flux and chemotaxis was compared. Expression of CXCR4-Lo-specific mRNA
in transfected RBL cell lines was confirmed by isoform-specific RT-PCR
(with Lo-346 primers) and Northern blot analysis of total RNA (data not
shown). Furthermore, as shown in Fig. 3
A, FACS analysis revealed
comparable levels of chemokine receptor surface expression on both
CXCR4- and CXCR4-Lo-transfected RBL cell lines. Upon treatment with
SDF-1
, there was a rapid
[Ca2+]i flux in
CXCR4-Lo-transfected RBL cells in a concentration-dependent manner
(Fig. 3
B). Similar results were obtained with SDF-1ß also
(data not shown). Altogether, CXCR4-Lo was found to be less potent and
efficacious (EC50 of
20 nM) in its response to
SDF-1, in comparison with CXCR4-transfected RBL cells
(EC50 of
6 nM) in the FLIPR
[Ca+2]i assay (Fig. 3
B). Similarly, the chemotactic response of
CXCR4-Lo-transfected RBL cells, although significant, was also
comparatively attenuated in the transwell migration assay (Fig. 3
C).
|
| Acknowledgments |
|---|
| Footnotes |
|---|
2 Abbreviations used in this paper: SDF-1, stromal cell-derived factor-1; EC, extracellular; EST, expressed sequence tag; FLIPR, fluorometric imaging plate reader; ORF, open reading frame; RBL, rat basophil leukemia cells; [Ca2+]i, intracellular Ca2+ concentration. ![]()
Received for publication March 17, 1999. Accepted for publication July 6, 1999.
| References |
|---|
|
|
|---|
, MIP-1ß receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 272:1955.[Abstract]
and eotaxin binding, respectively, but a second domain is essential for efficient receptor activation. J. Biol. Chem. 273:19972.
is a ligand for both CXC chemokine receptor-4 isoforms. J. Immunol. 158:3561.[Abstract]
activation of Gi2 are differentially expressed in vivo. Eur. J. Immunol. 27:2102.[Medline]
This article has been cited by other articles:
![]() |
J. Wang, Y. Shiozawa, J. Wang, Y. Wang, Y. Jung, K. J. Pienta, R. Mehra, R. Loberg, and R. S. Taichman The Role of CXCR7/RDC1 as a Chemokine Receptor for CXCL12/SDF-1 in Prostate Cancer J. Biol. Chem., February 15, 2008; 283(7): 4283 - 4294. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Kortesidis, A. Zannettino, S. Isenmann, S. Shi, T. Lapidot, and S. Gronthos Stromal-derived factor-1 promotes the growth, survival, and development of human bone marrow stromal stem cells Blood, May 15, 2005; 105(10): 3793 - 3801. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. E. Ehlert, C. A. Addison, M. D. Burdick, S. L. Kunkel, and R. M. Strieter Identification and Partial Characterization of a Variant of Human CXCR3 Generated by Posttranscriptional Exon Skipping J. Immunol., November 15, 2004; 173(10): 6234 - 6240. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. S. Haviv, W. J. van Houdt, B. Lu, D. T. Curiel, and Z. B. Zhu Transcriptional targeting in renal cancer cell lines via the human CXCR4 promoter Mol. Cancer Ther., June 1, 2004; 3(6): 687 - 691. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Garin, N. Tarantino, S. Faure, M. Daoudi, C. Lecureuil, A. Bourdais, P. Debre, P. Deterre, and C. Combadiere Two Novel Fully Functional Isoforms of CX3CR1 Are Potent HIV Coreceptors J. Immunol., November 15, 2003; 171(10): 5305 - 5312. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. D. Cristillo, M. J. Macri, and B. E. Bierer Differential chemokine expression profiles in human peripheral blood T lymphocytes: dependence on T-cell coreceptor and calcineurin signaling Blood, January 1, 2003; 101(1): 216 - 225. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. D. CRISTILLO, H. C. HIGHBARGER, R. L. DEWAR, D. S. DIMITROV, H. GOLDING, and B. E. BIERER Up-regulation of HIV coreceptor CXCR4 expression in human T lymphocytes is mediated in part by a cAMP-responsive element FASEB J, March 1, 2002; 16(3): 354 - 364. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. S. Taichman, C. Cooper, E. T. Keller, K. J. Pienta, N. S. Taichman, and L. K. McCauley Use of the Stromal Cell-derived Factor-1/CXCR4 Pathway in Prostate Cancer Metastasis to Bone Cancer Res., March 1, 2002; 62(6): 1832 - 1837. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Vinante, A. Rigo, M. T. Scupoli, and G. Pizzolo CD30 triggering by agonistic antibodies regulates CXCR4 expression and CXCL12 chemotactic activity in the cell line L540 Blood, January 1, 2002; 99(1): 52 - 60. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. M. Murphy, M. Baggiolini, I. F. Charo, C. A. Hebert, R. Horuk, K. Matsushima, L. H. Miller, J. J. Oppenheim, and C. A. Power International Union of Pharmacology. XXII. Nomenclature for Chemokine Receptors Pharmacol. Rev., March 1, 2000; 52(1): 145 - 176. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-R. Yu, K. W. C. Peden, M. B. Zaitseva, H. Golding, and J. M. Farber CCR9A and CCR9B: Two Receptors for the Chemokine CCL25/TECK/Ck{beta}-15 That Differ in Their Sensitivities to Ligand J. Immunol., February 1, 2000; 164(3): 1293 - 1305. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Sotsios, G. C. Whittaker, J. Westwick, and S. G. Ward The CXC Chemokine Stromal Cell-Derived Factor Activates a Gi-Coupled Phosphoinositide 3-Kinase in T Lymphocytes J. Immunol., December 1, 1999; 163(11): 5954 - 5963. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Brelot, N. Heveker, M. Montes, and M. Alizon Identification of Residues of CXCR4 Critical for Human Immunodeficiency Virus Coreceptor and Chemokine Receptor Activities J. Biol. Chem., July 28, 2000; 275(31): 23736 - 23744. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |